ZVRAZEVRA THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- $106M
- 351% YoY
- Operating margin
- -59.1%
- 84% YoY
- EBITDA
- −$59M
- 27% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$83M net debt
- AI in 10-K
- —
Red flags 2 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-2% of net incomeCash flow under 80% of net income
- Dilutive SBCFired12% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $29M | $10M | $27M | $24M | $106M | 351% |
| Operating income | $8M | −$43M | −$50M | −$87M | −$63M | 28% |
| Net income | −$9M | −$27M | −$46M | −$106M | $83M | 179% |
| Operating cash flow | $10M | −$19M | −$34M | −$70M | −$2M | 98% |
| Capex | $102K | $93K | $296K | $0 | $835K | |
| Stock-based comp | $2M | $4M | $6M | $15M | $13M | 15% |
| Buybacks | $3M | $5M | $3M | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $225K · 1
- Net
- −$225K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | — | 195 |
| FY2024 | — | — | — | 182 |
| FY2023 | — | — | — | 143 |